Evidence map›Paper›PMID 42648032›Full record

ArticleNeoplasia (New York, N.Y.)2026

Pdcd4-Rictor interaction suppresses mTORC2-PFKFB3 axis and tumorigenesis in NSCLC.

Qing Wang, Yumeng Xin, Elham Zokaei, Liang Zeng, Dava Piecoro, Min Chen, Yanquan Zhang, Katie S Yang, Chi Wang, Xiaoqi Liu and 1 more

Abstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Qing WangDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA; Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.. Electronic address: qwang8@uky.edu.
Yumeng XinDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Elham ZokaeiDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Liang ZengDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Dava PiecoroPathology and Laboratory Medicine, College of medicine, University of Kentucky, Lexington, Kentucky, USA.
Min ChenDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Yanquan ZhangDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Katie S YangMarkey Cancer Center, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Chi WangMarkey Cancer Center, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Xiaoqi LiuDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA; Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Hsin-Sheng YangDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA; Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.. Electronic address: hyang3@uky.edu.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate CancerR01CA272483 · NCI · UNIVERSITY OF KENTUCKY · PI XIAOQI LIU, Hsin-Sheng Yang · 2023 to 2026
$2.5M
Pdcd4-Rictor Interaction in Suppression of Lung TumorigenesisR01CA279455 · NCI · UNIVERSITY OF KENTUCKY · PI Hsin-Sheng Yang · 2023 to 2026
$2.1M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA272483NCI NIH HHS R01 CA279455
6 · The paper itself

Abstract

Programmed cell death 4 (Pdcd4) is a well-established tumor suppressor as well as an inhibitor of protein translation. Although Pdcd4-mediated translational repression contributes to tumor suppression, emerging evidence suggests that Pdcd4 also exerts translation-independent functions. In this study, we found that Pdcd4 suppresses tumorigenesis through disrupting mTORC2 complex formation by binding with the rapamycin-insensitive companion of mTOR (Rictor), a core component of the mTORC2 complex. Using deletion mapping and site-directed mutagenesis, we defined the Rictor-binding domain of Pdcd4 and identified three critical residues, R105, K108, and R110, for this interaction. Co-immunoprecipitation and in vitro kinase assays demonstrated that Pdcd4 binding to Rictor disrupted mTORC2 complex assembly and inhibited its kinase activity. Reverse phase protein array analysis revealed that 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key regulator of glycolysis, was markedly upregulated in Pdcd4-knockdown cells. Restoration of wild-type Pdcd4, but not a Rictor-binding-deficient mutant, reduced PFKFB3 protein abundance by promoting ubiquitin-proteasome-mediated degradation. Functionally, Pdcd4-Rictor interaction suppressed glycolytic activity and inhibited tumor cell proliferation in cultured cells and xenograft models. Consistent with these findings, non-small cell lung cancer (NSCLC) tissues exhibited significantly elevated protein levels of Rictor and PFKFB3 compared with adjacent normal tissues, with a positive correlation between their expression. Collectively, these results demonstrate that Pdcd4-Rictor interaction disrupts mTORC2 signaling and downregulates PFKFB3, which plays a critical role in suppressing NSCLC growth and glycolysis.

Indexed as

Apoptosis Regulatory ProteinsCarcinoma, Non-Small-Cell LungCell Transformation, NeoplasticLung NeoplasmsMechanistic Target of Rapamycin Complex 2Phosphofructokinase-2Rapamycin-Insensitive Companion of mTOR ProteinRNA-Binding ProteinsAnimalsCarcinogenesisCell Line, TumorCell ProliferationDisease Models, AnimalGene Expression Regulation, NeoplasticHumansMiceApoptosis Regulatory ProteinsMechanistic Target of Rapamycin Complex 2PDCD4 protein, humanPhosphofructokinase-2Rapamycin-Insensitive Companion of mTOR ProteinRICTOR protein, humanRNA-Binding ProteinsmTORC2Pdcd4PFKFB3Rictor

Identifiers

PMID42648032
PMCPMC13544097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.